Abstract 4752: Exon-16-skipping HER2 contributes to osimertinib-resistance through Src-independent manner in <i>EGFR</i> L858R/T790M-positive non-small-cell lung cancer
Chia‐Chi Hsu(National Taiwan University Hospital), Wei‐Yu Liao(National Taiwan University Hospital), Daniel Stetson(AstraZeneca (United States)), Kenneth S. Thress(AstraZeneca (United States)), Bin-Chi Liao(National Taiwan University Hospital), Aleksandra Markovets(AstraZeneca (United States))
Cited by 1
Related Papers
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2016|843
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
|JAMA Oncology|2018|689
The genome sequence of the orchid Phalaenopsis equestris
|Nature Genetics|2014|511